Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
BOSTON, May 01, 2018 -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will host a conference call on Tuesday, May 8, 2018 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2018.
Participants may access the call by dialing (844) 824-7428 in the U.S. or (973) 500-2177 outside the U.S. and referencing conference ID number 6639039. The call will also be webcast live on the Company's website at https://zafgen.gcs-web.com/events-and-presentations. A replay of this conference call will be available beginning at 7:30 p.m. ET on May 8, 2018 through May 15, 2018 by dialing (855) 859-2056 in the U.S. or (404) 537-3406 outside the U.S. To access the replay please provide conference ID number 6639039.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of complex metabolic diseases. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders, and its current disease areas of focus are type 2 diabetes, Prader-Willi syndrome and liver diseases. The company’s lead product candidate is ZGN-1061, a MetAP2 inhibitor in Phase 2 clinical development with unique properties that maximize impact on metabolic parameters relevant to the treatment of type 2 diabetes and other related metabolic disorders. In 2018, Zafgen plans to file an investigational new drug (IND) application with the U.S. FDA and initiate Phase 1 clinical trials for ZGN-1258, its new molecule for the treatment of Prader-Willi syndrome and potential other rare and serious forms of obesity. Learn more at www.zafgen.com.
Media/Investor Relations Contacts:
Zafgen, Inc.
Patricia Allen
Chief Financial Officer
617-648-9792
Media
Krystle Gibbs
Ten Bridge Communications
[email protected]
508-479-6358
Investors
John Woolford
Westwicke Partners
[email protected]
443-213-0506
